Stealth BioTherapeutics (NASDAQ:MITO) Announces Quarterly Earnings Results, Misses Expectations By $0.07 EPS

Share on StockTwits

Stealth BioTherapeutics (NASDAQ:MITO) posted its quarterly earnings data on Tuesday. The company reported ($0.03) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.07), MarketWatch Earnings reports.

Shares of MITO stock opened at $1.50 on Wednesday. The stock’s 50-day moving average price is $1.74 and its 200 day moving average price is $1.54. The stock has a market capitalization of $83.15 million, a PE ratio of 37.51 and a beta of 2.25. Stealth BioTherapeutics has a 52-week low of $1.19 and a 52-week high of $2.58.

About Stealth BioTherapeutics

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.

Featured Story: What is the accumulation/distribution indicator?

Earnings History for Stealth BioTherapeutics (NASDAQ:MITO)

Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with's FREE daily email newsletter.